Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
暂无分享，去创建一个
V. Calvez | A. Jahn | M. Lê | G. Peytavin | D. Descamps | J. Ousley | E. Szumilin | B. Schramm | B. Abdi | E. Temfack | A. Marcelin | A. Storto | S. Nicholas | J. Bitilinyu-Bangoh | T. Kalua